{"eventGroups":[{"description":"Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.\n\nLeuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days\n\nhematopoietic cell transplant: Conventional bone marrow transplant regimen.","id":"EG000","otherNumAffected":3,"otherNumAtRisk":7,"seriousNumAffected":0,"seriousNumAtRisk":7,"title":"Interventional - Received Leuprolide"},{"description":"Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.\n\nreduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"title":"Observational Arm"}],"frequencyThreshold":"0","otherEvents":[{"organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":10}],"term":"Hot Flashes"},{"organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":7},{"groupId":"EG001","numAffected":0,"numAtRisk":10}],"term":"Mood Liability"}]}